Zantac was taken off the market in April 2020 because the FDA found that its active ingredient, ranitidine, breaks down over time into a chemical called NDMA, a probable human carcinogen. Unlike contamination problems in other drugs, where a manufacturing error introduced an impurity, the issue with Zantac was baked into the molecule itself. The longer ranitidine sat on a shelf, or the warmer it got, the more NDMA it produced.
What NDMA Is and Why It Matters
NDMA (N-nitrosodimethylamine) is classified as a probable human carcinogen. It causes cancer reliably in animal studies, and while definitive proof of the same effect in humans is harder to establish, regulators treat it as dangerous. The FDA sets an acceptable daily intake limit of 96 nanograms per day for NDMA in medications. That’s an extraordinarily small amount, roughly equivalent to a few specks of dust by weight.
Small traces of NDMA show up in many everyday sources, including grilled meats, beer, and tobacco smoke. The concern with Zantac wasn’t that a little NDMA existed in each pill at the time of manufacture. It was that NDMA levels kept climbing the longer the drug was stored, eventually blowing past that 96-nanogram safety threshold.
The Problem Was the Molecule Itself
Ranitidine has an unusual chemical structure that contains a reactive component called a vinyl nitro group. When exposed to oxygen over time, the molecule slowly breaks apart, releasing two byproducts that recombine to form NDMA. Heat accelerates this process significantly, which is why pills stored in a hot car or a warm warehouse could end up with far higher NDMA levels than freshly manufactured ones.
This made the problem essentially unfixable through normal quality controls. With other drugs that had NDMA contamination issues (like certain blood pressure medications), manufacturers could clean up their production process and solve the problem. With ranitidine, the drug was generating NDMA on its own after leaving the factory. Researchers later proposed that oxygen-blocking packaging could theoretically halt the breakdown, but by then the regulatory decision had already been made.
How the Recall Unfolded
The timeline stretched about nine months from first alarm to full withdrawal. In the summer of 2019, an independent laboratory flagged NDMA in ranitidine samples. The FDA ran its own tests, confirmed the contamination at low levels, and issued a public warning in September 2019. At that point, the agency didn’t recommend that people stop taking the drug outright. It simply advised consumers to consider alternatives while the investigation continued.
Over the following months, continued testing revealed the critical finding: NDMA levels in ranitidine were not stable. They climbed with time and temperature, meaning that pills sitting in a medicine cabinet could exceed safe limits well before their expiration date. On April 1, 2020, the FDA requested that all manufacturers pull every prescription and over-the-counter ranitidine product from the U.S. market immediately.
Other Countries Followed
The European Medicines Agency took a similar path. In September 2020, its scientific committee recommended suspending all ranitidine medicines across the EU, and the European Commission made that suspension legally binding in November 2020. The suspension technically leaves open the possibility of ranitidine returning if manufacturers can demonstrate they’ve solved the NDMA formation problem, including providing data on whether NDMA might also form from ranitidine inside the human body. As of now, no company has met those conditions, and ranitidine remains unavailable in the EU.
Canada, Australia, and several other countries issued their own withdrawal orders around the same period. Ranitidine is effectively off the market worldwide.
Does Ranitidine Actually Cause Cancer?
This is where the story gets more complicated. The recall was based on the presence of a known carcinogen in the pills, not on direct evidence that Zantac users were developing cancer at higher rates. A large study using data from the UK Biobank found that regular ranitidine use was not associated with increased overall cancer risk. Researchers saw no meaningful link to colorectal, lung, breast, or prostate cancers. There was a tentative signal for liver cancer, but the authors noted it needed confirmation in other populations.
The gap between “this pill contains a carcinogen” and “this pill gave people cancer” became central to the massive wave of lawsuits that followed the recall.
The Legal Aftermath
Tens of thousands of people who had taken Zantac filed lawsuits claiming the drug caused their cancers. The legal outcomes have been split, with some plaintiffs winning settlements and others seeing their cases dismissed entirely.
On the settlement side, GlaxoSmithKline agreed to pay up to $2.2 billion to resolve roughly 80,000 state court cases, about 93% of the claims filed against it. Pfizer settled over 10,000 lawsuits on confidential terms. Sanofi announced in April 2024 that it was settling approximately 4,000 cases.
On the other side, the federal litigation took a very different turn. More than 50,000 federal cases were consolidated before a single judge in Florida, who issued a sweeping 341-page ruling in favor of the drug manufacturers. The judge concluded that the expert testimony linking Zantac to cancer didn’t meet the legal standard for scientific reliability, effectively gutting the plaintiffs’ case. That ruling is currently under appeal, with oral arguments scheduled for October 2025. Delaware’s Supreme Court reached a similar conclusion in July 2025, excluding expert reports that claimed Zantac caused cancer.
The result is a legal landscape where companies are paying billions in settlements (often to avoid the cost and uncertainty of individual trials) while simultaneously winning major rulings that say the science doesn’t support the cancer claims. Boehringer Ingelheim, one of the remaining defendants, continues to fight its cases and denies any wrongdoing.
What Replaced Zantac
Ranitidine belonged to a class of heartburn drugs called H2 blockers, which reduce stomach acid production. After the recall, the FDA pointed consumers toward other H2 blockers like famotidine (Pepcid), cimetidine (Tagamet), and nizatidine. These drugs work through the same mechanism but don’t share ranitidine’s unstable molecular structure, so they don’t generate NDMA over time. Proton pump inhibitors like omeprazole (Prilosec) are another widely available option for people who need stronger acid suppression.
A reformulated version of Zantac, called Zantac 360, appeared on shelves after the recall. Despite the familiar branding, it contains famotidine, not ranitidine. It’s a completely different drug sold under the old name.